SARASOTA, Fla., April 06, 2018 -- Roper Technologies, Inc. (NYSE:ROP) announced that its financial results for the first quarter of 2018, ended March 31, 2018, will be released before the market opens on Friday, April 20, 2018. A conference call to discuss these results has been scheduled for 8:30 AM ET on Friday, April 20, 2018. The call can be accessed via webcast or by dialing +1 800-239-9838 (US/Canada) or +1 323-794-2551, using confirmation code 7380704. Webcast information and conference call materials will be made available in the Investors section of Roper’s website prior to the start of the call.
About Roper Technologies
Roper Technologies is a constituent of the S&P 500, Fortune 1000, and the Russell 1000 indices. Roper operates businesses that design and develop software (both license and software-as-a-service) and engineered products and solutions for a variety of niche end markets. Additional information about Roper is available on the Company’s website at www.ropertech.com.
Contact Information:
Investor Relations
+1 (941) 556-2601
[email protected]


Street Poller Media and The Boom of the Street Interview Ad Industry
Jefferies Names AMEC Top China Semiconductor Equipment Pick
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition
Toyota Global Sales Fall as China Demand Slumps
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14%
Mercer International Stock Surges 45% on C$20 Million Canada Funding
Honda, Nissan Eye Shared Vehicle Software Platform by 2029
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules
Itochu Offers $1.56 Billion to Privatize Dentsu Soken
OpenAI AI Agent Swarm Behind Hugging Face Hack
PayPal Shares Sink as $50 Billion Takeover Bid Collapses
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 



